Fly News Breaks for November 13, 2019
Nov 13, 2019 | 08:42 EDT
Raymond James analyst Aaron Kessler raised his price target for Cardlytics to $53 from $40 following the company's "strong" Q3 results highlighted by by 70% billings growth and solid EBITDA leverage. In a research note to investors, Kessler says he is keeping his Outperform rating, given Cardlytics provides a compelling return on ad spend for marketers, the strong value proposition for financial institutions, strong competitive moats, a significant runway for key revenue drivers including MAUs and ARPU, and the expectation for 20%-plus long-term EBITDA margins.
News For CDLX From the Last 2 Days
Apr 15, 2021 | 06:45 EDT
Wells Fargo analyst Timothy Willi upgraded Cardlytics to Overweight from Equal Weight with a $150 price target. Willi believes the recent underperformance has created a favorable entry point for shares, and sees several fundamental catalysts over the near to medium term, the analyst tells investors in a research note. The analyst views the risk/reward as favorable at current levels and the liquidity position as stable.